DOCSLIB.ORG

Weisz Ora a Curriculum Vitae.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2007- University of Pittsburgh School of Medicine Professor of Medicine and Cell Biology 2003-2007 University of Pittsburgh Health Sciences Assistant Director Office of Academic Career Development 2001- University of Pittsburgh School of Medicine Affiliate Faculty McGowan Institute for Regenerative Medicine 2001-2007 University of Pittsburgh School of Medicine Associate Professor of Medicine and Cell Biology and Physiology (tenured) 1995-2001 University of Pittsburgh School of Medicine Assistant Professor of Medicine (Renal- Electrolyte Division) and Cell Biology and Physiology MEMBERSHIPS IN PROFESSIONAL and SCIENTIFIC SOCIETIES Yale Science and Engineering Association 1984-88 Sigma Xi 1984- American Society for Cell Biology 1990- American Assn. for the Advancement of Science 1995- Association for Women in Science 1997-2005 American Society of Nephrology 2000- The American Physiological Society 2004- National Kidney Foundation 2007-2011 HONORS Presidential Scholar finalist (top 1000 U.S. high school students) 1980 B.S., Cum Laude, Yale University 1984 Sigma Xi 1984 NIH NRSA, Postdoctoral fellowship 1990-1993 Univ. of Pittsburgh Senior Vice-Chancellor’s Research Seminar Series 2000 American Journal of Physiology Star Reviewer 2007 Academy of Master Educators, University of Pittsburgh School of Medicine 2009- Fellow, Executive Leadership in Academic Medicine (ELAM) Program 2010-2011 Distinguished Mentor Award Finalist, School of Medicine 2011 Member, ICRE Mentoring Network 2012- Elected to Johns Hopkins Society of Scholars 2014 Distinguished Mentor Award, School of Medicine 2014 University of Pittsburgh Postdoctoral Association Advocate Award 2015 Elected to Council, American Society of Cell Biology 2015-2018 Fellow, American Physiological Society 2019 Fellow, American Society of Cell Biology 2020 PUBLICATIONS Original peer reviewed articles 1. Wood TG, Weisz OA, and Kozarich JW (1984) Acyl-enzyme exchange detection by intermolecular oxygen scrambling: an application of the 18O-isotope effect in 13C NMR. J Amer Chem Soc. 106:2222- 2223. Curr cu um V tae Ora A. We sz 2 2. Brandley BK, Weisz OA, and Schnaar RL (1987) Cell attachment and long-term growth on derivatizable polyacrylamide surfaces. J Biol Chem. 262:6431-6437. 3. Weisz OA and Schnaar RL (1990) Hepatocyte-mediated Coenzyme A transfer to carbohydrate- derivatized surfaces. Biochem Biophys Res Commun.167:67-73. 4. Rice KG, Weisz OA, Barthel T, Lee RT, and Lee YC (1990) Defined geometry of binding between triantennary glycopeptide and the asialoglycoprotein receptor of rat hepatocytes. J Biol Chem. 265:18429-18434. 5. Weisz OA and Schnaar RL (1991) Hepatocyte adhesion to carbohydrate-derivatized surfaces I Surface topography of the rat hepatic lectin. J Cell Biol. 115:485-493. PMCID: 2289166. 6. Weisz OA, and Schnaar RL (1991) Hepatocyte adhesion to carbohydrate-derivatized surfaces II Regulation of cytoskeletal organization and cell morphology. J Cell Biol. 115:495-504. PMCID: 2289152. 7. Weisz OA, Machamer CE, and Hubbard AL (1992) Rat liver dipeptidylpeptidase IV contains competing apical and basolateral targeting information. J Biol Chem. 267:22282-22288. 8. Weisz OA, Swift AM, and Machamer CE (1993) Oligomerization of a membrane protein correlates with its retention in the Golgi complex. J Cell Biol. 122:1185-1197 (featured in the Headlines section of Trends in Cell Biology 1993;3). PMCID: 2119850. 9. Jiang XS, Hill WG, Pilewski JM, and Weisz OA (1997) Glycosylation differences between a cystic fibrosis and rescued cell line are not CFTR-dependent. Am J Physiol- Lung Cell and Mol Physiol. 273:L913-L920. 10. Henkel JR and Weisz OA (1998) Influenza virus M2 protein slows transport along the secretory pathway. J Biol Chem. 273:6518-6524. 11. Henkel JR, Apodaca G, Altschuler Y, Hardy S, and Weisz OA (1998) Selective perturbation of apical membrane traffic by expression of influenza M2, an acid-activated ion channel, in polarized Madin-Darby canine kidney cells. Mol Biol Cell. 9:2477-2490. PMCID: 25516. 12. Rokaw MD, Wang J, Edinger RS, Weisz OA, Hui D, Middleton P, Shlyonsky V, Berdiev B K, Ismailov, I, Eaton DC, Benos DJ, and Johnson JP (1998) Carboxylmethylation of the beta subunit of xENaC regulates channel activity. J Biol Chem. 273:28746-28751. 13. Henkel JR, Popovich JL, Gibson GA, Watkins SC, and Weisz OA (1999) Selective perturbation of early endosome and/or TGN pH but not lysosome pH by dose-dependent expression of influenza M2 protein. J Biol Chem. 274:9854-9860. 14. Sevier CS, Weisz OA, Davis M, and Machamer CE (2000) Efficient export of the vesicular stomatitis virus glycoprotein from the endoplasmic reticulum requires a signal in the cytoplasmic tail that includes both tyrosine-based and di-acidic motifs. Mol Biol Cell. 11:13-22. PMCID: 14753. 15. Altschuler Y, Kinlough CL, Poland PA, Bruns JB, Apodaca G, Weisz OA, and Hughey RP (2000) Clathrin mediated endocytosis of MUC1 is modulated by its glycosylation state. Mol Biol Cell. 11:819-831. PMCID: 14813. 16. Henkel JR, Gibson GA, Poland PA, Ellis MA, Hughey RP, and Weisz OA (2000) Influenza M2 proton channel activity selectively inhibits TGN release of apical membrane and secreted proteins in polarized MDCK cells. J Cell Biol. 148:495-504 (highlighted in the In Brief section of Journal of Cell Biology 2000;148:1-2). PMCID: 2174804. Curr cu um V tae Ora A. We sz 3 17. Howard M, Jiang X, Beer Stolz D, Hill WG, Johnson JA, Watkins SC, Frizzell RA, Bruton CM, Robbins PD, and Weisz OA (2000) Forskolin-induced apical membrane insertion of virally-expressed, epitope- tagged CFTR in polarized MDCK cells. Am J Physiol- Cell Physiol. 279:C375-C382. 18. Weisz OA, Gibson GA, Roder J, and Jeromin A (2000) Overexpression of frequenin, a modulator of phosphatidylinositol 4-kinase, inhibits biosynthetic delivery to the apical surface of polarized Madin-Darby canine kidney cells. J Biol Chem. 275:24341-24347. 19. Gibson GA, Hill WG, and Weisz OA (2000) Evidence against the acidification hypothesis in cystic fibrosis. Am J Physiol- Cell Physiol. 279:C1088-1099. 20. Weisz OA, Wang J-M, Edinger RS, and Johnson JP (2000) Non-coordinate regulation of endogenous ENaC subunit expression at the apical membrane of A6 cells in response to various transporting conditions. J Biol Chem. 275:39886-39893. 21. Ihrke G, Bruns JR, Luzio JP, and Weisz OA. (2001) A novel lysosomal delivery route via the apical surface identified by the trafficking of endolyn in MDCK cells. EMBO J. 20:6256-6264. PMCID: 125743. 22. Bruns JR, Ellis MA, Jeromin A, and Weisz OA (2002) Multiple roles for phosphatidylinositol 4-kinase in biosynthetic transport in polarized MDCK cells. J Biol Chem. 277:2012-2018. 23. Lee E, Marcucci M, Daniell L, Pypaert M, Weisz OA, Ochoa, G-C, Farsad, K, Wenk, MR, and De Camilli, P (2002) Amphiphysin 2 (Bin1) and T-tubule biogenesis in muscle. Science. 297:1193-1196 (highlighted by the Faculty of 1000). 24. Puthenveedu M, Bruns JR, Weisz OA, and Linstedt, AD (2003) Basolateral cycling mediated by a lumenal domain targeting determinant. Mol Biol Cell. 14:1801-1807. PMCID: 165078. 25. Chen C, Weisz OA, Stolz DB, Watkins SC, and Montelaro RC (2004) Differential effects of actin cytoskeleton dynamics on equine infectious anemia virus particle production. J Virol. 78:882-891. PMCID: 368807. 26. Potter BA, Ihrke G, Bruns JR, Weixel KM, and Weisz OA (2004) Specific N-glycans direct apical delivery of transmembrane, but not soluble or GPI-anchored forms of endolyn in MDCK cells. Mol Biol Cell. 15:1407-1416 (highlighted by the Faculty of 1000). PMCID: 363156. 27. Mohan S, Bruns JR, Weixel KM, Edinger RS, Bruns JB, Kleyman TR, Johnson JP, and Weisz OA (2004) Differential current decay profiles of ENaC subunit combinations in polarized renal epithelial cells. J Biol Chem. 279:32071-32078. 28. Ellis MA, Miedel MT, Guerriero CJ, and Weisz OA (2004) ARF1-independent protein sorting and export from the trans-Golgi network. J Biol Chem. 279:52735-52743. 29. Weixel KM, Blumental-Perry A, Watkins SC, Aridor M, and Weisz OA (2005) Distinct Golgi populations of phosphatidylinositol 4-phosphate regulated by phosphatidylinositol 4-kinases J Biol Chem. 280:10501-10508. 30. Jin S, Zhang B, Weisz OA, and Montelaro RC (2005) Receptor-mediated entry by equine infectious anemia virus utilizes a pH-dependent endocytic pathway. J Virol. 79:14489-14497. PMCID: 1287590. 31. Chen C, Vincent O, Jin J, Weisz OA, and Montelaro RC (2005) Functions of early (AP-2) and late (AIP1/ALIX) endocytic proteins in equine infectious anemia virus budding. J Biol Chem. 280:40474- 40480. 32. Potter BA, Weixel KM, Bruns JR, Ihrke G, and Weisz OA (2006) N-glycans mediate apical recycling of the sialomucin endolyn in polarized MDCK cells. Traffic. 7:146-154 (highlighted by the Faculty of 1000). Curr cu um V tae Ora A. We sz 4 33. Kinlough CL, McMahan RJ, Poland PA, Bruns JB, Harkleroad KL, Stremple RJ, Kashlan OB, Weixel KM, Weisz OA, and Hughey RP (2006). MUC1 recycling is dependent on its palmitoylation. J Biol Chem. 281:12112-12122. 34. Miedel MT, Weixel KM, Bruns JR, Traub LM, and Weisz OA (2006) Posttranslational cleavage and adaptor protein complex-dependent trafficking of mucolipin-1. J Biol Chem. 281:12751-12759. 35. Guerriero CJ, Weixel KM, Bruns JR, and Weisz OA (2006) Phosphatidylinositol 5-kinase stimulates apical biosynthetic delivery via an Arp2/3-dependent mechanism. J Biol Chem. 281:15376-15384. 36. Ellis MA, and Weisz OA (2006) In vitro assays differentially recapitulate protein export from the trans- Golgi network. Anal Biochem. 354:314-315. 37. Blumental-Perry A, Haney CJ, Weixel KM, Watkins SC, Weisz OA, and Aridor M (2006) Phosphatidylinositol 4-phosphate formation at ER exit sites regulates ER export. Dev Cell. 11:671-682 (highlighted by the Faculty of 1000). 38. Lu C, Walker WH, Sun J, Weisz OA, Gibbs RB, Witchel SF, Sperling MA, and Menon RK (2006) Insulin-like peptide 6 (Insl6): Characterization of secretory status and post-translational modifications.
Recommended publications
  • Supplementary Table 1: Adhesion Genes Data Set

    Supplementary Table 1: Adhesion Genes Data Set

    Supplementary Table 1: Adhesion genes data set PROBE Entrez Gene ID Celera Gene ID Gene_Symbol Gene_Name 160832 1 hCG201364.3 A1BG alpha-1-B glycoprotein 223658 1 hCG201364.3 A1BG alpha-1-B glycoprotein 212988 102 hCG40040.3 ADAM10 ADAM metallopeptidase domain 10 133411 4185 hCG28232.2 ADAM11 ADAM metallopeptidase domain 11 110695 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 195222 8038 hCG40937.4 ADAM12 ADAM metallopeptidase domain 12 (meltrin alpha) 165344 8751 hCG20021.3 ADAM15 ADAM metallopeptidase domain 15 (metargidin) 189065 6868 null ADAM17 ADAM metallopeptidase domain 17 (tumor necrosis factor, alpha, converting enzyme) 108119 8728 hCG15398.4 ADAM19 ADAM metallopeptidase domain 19 (meltrin beta) 117763 8748 hCG20675.3 ADAM20 ADAM metallopeptidase domain 20 126448 8747 hCG1785634.2 ADAM21 ADAM metallopeptidase domain 21 208981 8747 hCG1785634.2|hCG2042897 ADAM21 ADAM metallopeptidase domain 21 180903 53616 hCG17212.4 ADAM22 ADAM metallopeptidase domain 22 177272 8745 hCG1811623.1 ADAM23 ADAM metallopeptidase domain 23 102384 10863 hCG1818505.1 ADAM28 ADAM metallopeptidase domain 28 119968 11086 hCG1786734.2 ADAM29 ADAM metallopeptidase domain 29 205542 11085 hCG1997196.1 ADAM30 ADAM metallopeptidase domain 30 148417 80332 hCG39255.4 ADAM33 ADAM metallopeptidase domain 33 140492 8756 hCG1789002.2 ADAM7 ADAM metallopeptidase domain 7 122603 101 hCG1816947.1 ADAM8 ADAM metallopeptidase domain 8 183965 8754 hCG1996391 ADAM9 ADAM metallopeptidase domain 9 (meltrin gamma) 129974 27299 hCG15447.3 ADAMDEC1 ADAM-like,
  • Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes

    Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs.
  • Adherence of Mycoplasma Gallisepticum to Human Erythrocytes M

    Adherence of Mycoplasma Gallisepticum to Human Erythrocytes M

    INFECTION AND IMMUNITY, Aug. 1978, p. 365-372 Vol. 21, No. 2 0019-9567/78/0021-0365$02.00/0 Copyright i 1978 American Society for Microbiology Printed in U.S.A. Adherence of Mycoplasma gallisepticum to Human Erythrocytes M. BANAI,1 I. KAHANE,' S. RAZINl* AND W. BREDT2 Biomembrane Research Laboratory, Department of Clinical Microbiology, The Hebrew University- Hadassah Medical School, Jerusalem, Israel,' and Institute for General Hygiene and Bacteriology, Center for Hygiene, Albert-Ludwigs- Universitat, D- 7800 Freiburg, West Germany Received for publication 7 February 1978 Pathogenic mycoplasmas adhere to and colonize the epithelial lining of the respiratory and genital tracts ofinfected animals. An experimental system suitable for the quantitative study of mycoplasma adherence has been developed by us. The system consists of human erythrocytes (RBC) and the avian pathogen Mycoplasma gallisepticum, in which membrane lipids were labeled. The amount of mycoplasma cells attached to the RBC, which was determined according to radioactivity measurements, decreased on increasing the pH or ionic strength of the attachment mixture. Attachment followed first-order kinetics and depended on temperature. The mycoplasma cell population remaining in the supernatant fluid after exposure to RBC showed a much poorer ability to attach to RBC during a second attachment test, indicating an unequal distribution of binding sites among cells within a given population. The gradual removal of sialic acid residues from the RBC by neuraminidase was accompanied by a decrease in mycoplasma attachment. Isolated glycophorin, the RBC membrane glycoprotein carrying almost all the sialic acid moieties ofthe RBC, inhibited M. gallisepticum attachment, whereas asialoglycophorin and sialic acid itself were very poor inhibitors of attachment.
  • Human Lectins, Their Carbohydrate Affinities and Where to Find Them

    Human Lectins, Their Carbohydrate Affinities and Where to Find Them

    biomolecules Review Human Lectins, Their Carbohydrate Affinities and Where to Review HumanFind Them Lectins, Their Carbohydrate Affinities and Where to FindCláudia ThemD. Raposo 1,*, André B. Canelas 2 and M. Teresa Barros 1 1, 2 1 Cláudia D. Raposo * , Andr1 é LAQVB. Canelas‐Requimte,and Department M. Teresa of Chemistry, Barros NOVA School of Science and Technology, Universidade NOVA de Lisboa, 2829‐516 Caparica, Portugal; [email protected] 12 GlanbiaLAQV-Requimte,‐AgriChemWhey, Department Lisheen of Chemistry, Mine, Killoran, NOVA Moyne, School E41 of ScienceR622 Co. and Tipperary, Technology, Ireland; canelas‐ [email protected] NOVA de Lisboa, 2829-516 Caparica, Portugal; [email protected] 2* Correspondence:Glanbia-AgriChemWhey, [email protected]; Lisheen Mine, Tel.: Killoran, +351‐212948550 Moyne, E41 R622 Tipperary, Ireland; [email protected] * Correspondence: [email protected]; Tel.: +351-212948550 Abstract: Lectins are a class of proteins responsible for several biological roles such as cell‐cell in‐ Abstract:teractions,Lectins signaling are pathways, a class of and proteins several responsible innate immune for several responses biological against roles pathogens. such as Since cell-cell lec‐ interactions,tins are able signalingto bind to pathways, carbohydrates, and several they can innate be a immuneviable target responses for targeted against drug pathogens. delivery Since sys‐ lectinstems. In are fact, able several to bind lectins to carbohydrates, were approved they by canFood be and a viable Drug targetAdministration for targeted for drugthat purpose. delivery systems.Information In fact, about several specific lectins carbohydrate were approved recognition by Food by andlectin Drug receptors Administration was gathered for that herein, purpose. plus Informationthe specific organs about specific where those carbohydrate lectins can recognition be found by within lectin the receptors human was body.
  • Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease

    Development and Validation of a Protein-Based Risk Score for Cardiovascular Outcomes Among Patients with Stable Coronary Heart Disease

    Supplementary Online Content Ganz P, Heidecker B, Hveem K, et al. Development and validation of a protein-based risk score for cardiovascular outcomes among patients with stable coronary heart disease. JAMA. doi: 10.1001/jama.2016.5951 eTable 1. List of 1130 Proteins Measured by Somalogic’s Modified Aptamer-Based Proteomic Assay eTable 2. Coefficients for Weibull Recalibration Model Applied to 9-Protein Model eFigure 1. Median Protein Levels in Derivation and Validation Cohort eTable 3. Coefficients for the Recalibration Model Applied to Refit Framingham eFigure 2. Calibration Plots for the Refit Framingham Model eTable 4. List of 200 Proteins Associated With the Risk of MI, Stroke, Heart Failure, and Death eFigure 3. Hazard Ratios of Lasso Selected Proteins for Primary End Point of MI, Stroke, Heart Failure, and Death eFigure 4. 9-Protein Prognostic Model Hazard Ratios Adjusted for Framingham Variables eFigure 5. 9-Protein Risk Scores by Event Type This supplementary material has been provided by the authors to give readers additional information about their work. Downloaded From: https://jamanetwork.com/ on 10/02/2021 Supplemental Material Table of Contents 1 Study Design and Data Processing ......................................................................................................... 3 2 Table of 1130 Proteins Measured .......................................................................................................... 4 3 Variable Selection and Statistical Modeling ........................................................................................
  • Prospects for Using Expression Patterns of Paramyxovirus Receptors As Biomarkers for Oncolytic Virotherapy

    Prospects for Using Expression Patterns of Paramyxovirus Receptors As Biomarkers for Oncolytic Virotherapy

    cancers Review Prospects for Using Expression Patterns of Paramyxovirus Receptors as Biomarkers for Oncolytic Virotherapy Olga V. Matveeva 1,* and Svetlana A. Shabalina 2,* 1 Sendai Viralytics LLC, 23 Nylander Way, Acton, MA 01720, USA 2 National Center for Biotechnology Information, National Library of Medicine, National Institutes of Health, Bethesda, MD 20894, USA * Correspondence: [email protected] (O.V.M.); [email protected] (S.A.S.) Received: 27 October 2020; Accepted: 1 December 2020; Published: 5 December 2020 Simple Summary: Some non-pathogenic viruses that do not cause serious illness in humans can efficiently target and kill cancer cells and may be considered candidates for cancer treatment with virotherapy. However, many cancer cells are protected from viruses. An important goal of personalized cancer treatment is to identify viruses that can kill a certain type of cancer cells. To this end, researchers investigate expression patterns of cell entry receptors, which viruses use to bind to and enter host cells. We summarized and analyzed the receptor expression patterns of two paramyxoviruses: The non-pathogenic measles and the Sendai viruses. The receptors for these viruses are different and can be proteins or lipids with attached carbohydrates. This review discusses the prospects for using these paramyxovirus receptors as biomarkers for successful personalized virotherapy for certain types of cancer. Abstract: The effectiveness of oncolytic virotherapy in cancer treatment depends on several factors, including successful virus delivery to the tumor, ability of the virus to enter the target malignant cell, virus replication, and the release of progeny virions from infected cells. The multi-stage process is influenced by the efficiency with which the virus enters host cells via specific receptors.
  • Remodelling and Glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)

    Remodelling and Glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF)

    (19) *EP002042196A2* (11) EP 2 042 196 A2 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 01.04.2009 Bulletin 2009/14 A61K 47/48 (2006.01) C07K 1/00 (2006.01) C07K 1/13 (2006.01) A61K 38/14 (2006.01) (2006.01) (2006.01) (21) Application number: 09000818.6 A61K 38/16 A61K 38/24 A61K 38/26 (2006.01) A61K 38/28 (2006.01) (2006.01) (2006.01) (22) Date of filing: 09.10.2002 A61K 38/29 A61K 38/30 A61K 38/43 (2006.01) C07K 9/00 (2006.01) C07K 14/475 (2006.01) C07K 14/59 (2006.01) C07K 14/61 (2006.01) C07K 14/525 (2006.01) C07K 14/56 (2006.01) C07K 14/565 (2006.01) C12N 9/64 (2006.01) C12N 9/22 (2006.01) C07K 19/00 (2006.01) C07K 14/79 (2006.01) C07H 19/10 (2006.01) (84) Designated Contracting States: • Zopf, David AT BE BG CH CY CZ DE DK EE ES FI FR GB GR Wayne, PA 19087 (US) IE IT LI LU MC NL PT SE SK TR • Bayer, Robert San Diego, CA 92122 (US) (30) Priority: 10.10.2001 US 328523 P • Bowe, Caryn 19.10.2001 US 344692 P Doylestown, PA 18901 (US) 28.11.2001 US 334233 P • Hakes, David 28.11.2001 US 334301 P Willow Grove, PA 19090 (US) 07.06.2002 US 387292 P • Chen, Xi 25.06.2002 US 391777 P Lansdale, PA 19446 (US) 17.07.2002 US 396594 P 16.08.2002 US 404249 P (74) Representative: Watkins, Charlotte Helen 28.08.2002 US 407527 P Harrison Goddard Foote Belgrave Hall (62) Document number(s) of the earlier application(s) in Belgrave Street accordance with Art.
  • 1 Novel Expression Signatures Identified by Transcriptional Analysis

    1 Novel Expression Signatures Identified by Transcriptional Analysis

    ARD Online First, published on October 7, 2009 as 10.1136/ard.2009.108043 Ann Rheum Dis: first published as 10.1136/ard.2009.108043 on 7 October 2009. Downloaded from Novel expression signatures identified by transcriptional analysis of separated leukocyte subsets in SLE and vasculitis 1Paul A Lyons, 1Eoin F McKinney, 1Tim F Rayner, 1Alexander Hatton, 1Hayley B Woffendin, 1Maria Koukoulaki, 2Thomas C Freeman, 1David RW Jayne, 1Afzal N Chaudhry, and 1Kenneth GC Smith. 1Cambridge Institute for Medical Research and Department of Medicine, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK 2Roslin Institute, University of Edinburgh, Roslin, Midlothian, EH25 9PS, UK Correspondence should be addressed to Dr Paul Lyons or Prof Kenneth Smith, Department of Medicine, Cambridge Institute for Medical Research, Addenbrooke’s Hospital, Hills Road, Cambridge, CB2 0XY, UK. Telephone: +44 1223 762642, Fax: +44 1223 762640, E-mail: [email protected] or [email protected] Key words: Gene expression, autoimmune disease, SLE, vasculitis Word count: 2,906 The Corresponding Author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive licence (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group Ltd and its Licensees to permit this article (if accepted) to be published in Annals of the Rheumatic Diseases and any other BMJPGL products to exploit all subsidiary rights, as set out in their licence (http://ard.bmj.com/ifora/licence.pdf). http://ard.bmj.com/ on September 29, 2021 by guest. Protected copyright. 1 Copyright Article author (or their employer) 2009.
  • Functional Role of the Overexpression of the Myelin and Lymphocyte

    Functional Role of the Overexpression of the Myelin and Lymphocyte

    Functional role of the overexpression of the myelin and lymphocyte protein MAL in Schwann cells Inauguraldissertation Zur Erlangung der Würde eines Doktors der Philosophie Vorgelegt der Philosophisch‐Naturwissenschaftlichen Fakultät der Universität Basel von Daniela Schmid aus Ramsen (SH) Basel, 2013 Genehmigt von der Philosophisch-Naturwissenschaftlichen Fakultät auf Antrag von: Prof. M.A. Rüegg (Fakultätsverantwortlicher) Prof. N. Schaeren-Wiemers (Dissertationsleiterin) Prof. J. Kapfhammer (Korreferent) Basel, den 18. Juni 2013 Prof. J. Schibler (Dekan) To Michael 1. Acknowledgments 1. ACKNOWLEDGMENTS ................................................................................................................................ 6 2. ABBREVIATIONS ......................................................................................................................................... 7 3. SUMMARY ............................................................................................................................................... 10 4. INTRODUCTION ........................................................................................................................................ 11 4.1. THE NERVOUS SYSTEM AND MYELIN SHEATH COMPOSITION ..................................................................................... 11 4.2. SCHWANN CELL ORIGIN AND LINEAGE ................................................................................................................. 12 4.3. THE FUNCTIONAL ROLE OF THE BASAL LAMINA .....................................................................................................
  • Functional Significance of Glycoprotein Clearance by The

    Functional Significance of Glycoprotein Clearance by The

    Washington University in St. Louis Washington University Open Scholarship All Theses and Dissertations (ETDs) January 2009 Functional Significance of Glycoprotein Clearance by the Asialoglycoprotein Receptor and the Mannose/GalNAc-4-SO4 Receptor Lindsay Steirer Taylor Washington University in St. Louis Follow this and additional works at: https://openscholarship.wustl.edu/etd Recommended Citation Steirer Taylor, Lindsay, "Functional Significance of Glycoprotein Clearance by the Asialoglycoprotein Receptor and the Mannose/ GalNAc-4-SO4 Receptor" (2009). All Theses and Dissertations (ETDs). 333. https://openscholarship.wustl.edu/etd/333 This Dissertation is brought to you for free and open access by Washington University Open Scholarship. It has been accepted for inclusion in All Theses and Dissertations (ETDs) by an authorized administrator of Washington University Open Scholarship. For more information, please contact [email protected]. WASHINGTON UNIVERSITY IN ST. LOUIS Division of Biology and Biomedical Sciences Molecular Cell Biology Dissertation Examination Committee: Jacques U. Baenziger, Chair Stuart Kornfeld Timothy Ley Kelle Moley Douglas Tollefsen Lijuan Zhang Functional Significance of Glycoprotein Clearance by the Asialoglycoprotein Receptor and the Mannose/GalNAc-4-SO4 Receptor by Lindsay Michelle Steirer Taylor A dissertation presented to the Graduate School of Arts and Sciences of Washington University in partial fulfillment of the requirements for the degree of Doctor of Philosophy August 2009 Saint Louis, MO Acknowledgments I thank Jacques Baenziger for his support, insight, persistence and assistance on my often difficult and confusing, yet fascinating project, and for being a great friend. I would like to thank my current and past lab members, Mary Beranek, Dorothy Fiete, Yiling Mi, and Eric Park for their continued support through my scientific and life journey.
  • Insights Into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma

    Insights Into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma

    pharmaceuticals Review Insights into an Immunotherapeutic Approach to Combat Multidrug Resistance in Hepatocellular Carcinoma Aswathy R. Devan 1,†, Ayana R. Kumar 1,†, Bhagyalakshmi Nair 1, Nikhil Ponnoor Anto 2,‡ , Amitha Muraleedharan 2,‡ , Bijo Mathew 3, Hoon Kim 4,* and Lekshmi R. Nath 1,* 1 Department of Pharmacognosy, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India; [email protected] (A.R.D.); [email protected] (A.R.K.); [email protected] (B.N.) 2 The Shraga Segal Department of Microbiology, Immunology, and Genetics, Faculty of Health Sciences, Ben-Gurion University of the Negev, P.O.B. 653, Beer Sheva 84105, Israel; [email protected] (N.P.A.); [email protected] (A.M.) 3 Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Science Campus, Kochi 682041, Kerala, India; [email protected] 4 Department of Pharmacy, and Research Institute of Life Pharmaceutical Sciences, Sunchon National University, Suncheon 57922, Korea * Correspondence: [email protected] (H.K.); [email protected] (L.R.N.) † These authors contributed equally. ‡ These authors contributed equally. Abstract: Hepatocellular carcinoma (HCC) has emerged as one of the most lethal cancers worldwide because of its high refractoriness and multi-drug resistance to existing chemotherapies, which leads to poor patient survival. Novel pharmacological strategies to tackle HCC are based on oral multi-kinase Citation: Devan, A.R.; Kumar, A.R.; inhibitors like sorafenib; however, the clinical use of the drug is restricted due to the limited survival Nair, B.; Anto, N.P.; Muraleedharan, rate and significant side effects, suggesting the existence of a primary or/and acquired drug-resistance A.; Mathew, B.; Kim, H.; Nath, L.R.
  • Decrease of Sialic Acid Residues As an Eat-Me Signal on the Surface of Apoptotic Lymphocytes

    Decrease of Sialic Acid Residues As an Eat-Me Signal on the Surface of Apoptotic Lymphocytes

    Research Article 3347 Decrease of sialic acid residues as an eat-me signal on the surface of apoptotic lymphocytes Hanna Marie Meesmann1, Eva-Marie Fehr1, Sonja Kierschke1, Martin Herrmann2, Rostyslav Bilyy3, Petra Heyder1, Norbert Blank1, Stefan Krienke1, Hanns-Martin Lorenz1 and Martin Schiller1,* 1Department of Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, Germany 2Institute for Clinical Immunology and Rheumatology, Department of Internal Medicine 3, University Hospital Erlangen, 91054 Erlangen, Germany 3Institute of Cell Biology, National Academy of Sciences of Ukraine, Drahomanov Street 14/16, 79005 Lviv, Ukraine *Author for correspondence ([email protected]) Accepted 14 June 2010 Journal of Cell Science 123, 3347-3356 © 2010. Published by The Company of Biologists Ltd doi:10.1242/jcs.066696 Summary The silent clearance of apoptotic cells is essential for cellular homeostasis in multicellular organisms, and several mediators of apoptotic cell recognition have been identified. However, the distinct mechanisms involved are not fully deciphered yet. We analyzed alterations of the glycocalyx on the surfaces of apoptotic cells and its impact for engulfment. After apoptosis induction of lymphocytes, a decrease of 2,6-terminal sialic acids and sialic acids in 2,3-linkage with galactose was observed. Similar changes were to be found on the surface of apoptotic membrane blebs released during early stages of apoptosis, whereas later released blebs showed no impaired, but rather an increased, exposure of sialic acids. We detected an exposure of fucose residues on the surface of apoptotic-cell-derived membrane blebs. Cleavage by neuraminidase of sialic acids, as well as lectin binding to sialic acids on the surfaces, enhanced the engulfment of apoptotic cells and blebs.